Clinical Trial Search

Primary: Retention, Measured as the Number of HIV Exposure Events That Were Retained in Care at the 24 Week Follow-up Visit — 125; 157 HIV Exposure Events — p=<0.05

Primary: Medication Regimen Completion Rates — 57; 28; 15 participants

Primary: Evidence of Toxicity. Toxicity Was Measured as Any Adverse Event; Nausea, Vomiting, Diarrhea. Elevated Liver Function Tests. — 4; 4 adverse events

Primary: Number of Adverse Event Occurrences — 38; 28; 28; 14 events

Primary: Blood Exposure — 1.9; 1.9 Number of Glove Pairs Used Per Razor Bla

Primary: Engagement in Care (Implementation Component) — 1; 1 Participants

Primary: Number of Participants With Early Discontinuation From Randomized Human Immunodeficiency Virus Postexposure Prophylaxis (HIV PEP) — 10; 15 participants — p=0.2434

Primary: Proportion of Participants Who Did Not Complete the 28-day PEP Regimen — 114 Participants

Primary: Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants — 0.65; 0.50; 1.99 events per 100 person years — p=<0.001

Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened

Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale

Primary: WHO Anthropometric Measure of Weight-for-Age Z-Score — -0.32; -0.80; -1.59; -0.29 Z-scores

Primary: Proportion of Sexual Exposures Covered by Pre- and Post-exposure Dosing — 75; 56; 52; 85 percentage of sexual exposures

Primary: Percentage of Tested Participants Newly Diagnosed as HIV Infected — 6; 3 percentage of tested that are positive

Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months

Primary: Prevalence of HIV Infection — 6 Participants

Primary: Efficacy as Assessed by the Number of Participants Who Were HIV Positive at 6 Months — 0 participants

Primary: Number of Participants Achieving Appropriate Levels of Tenofovir-diphosphate (TFV-DP) at 6-month Follow-up — 78; 39 Participants

Primary: HIV Testing Related Knowledge and Practice — 17.17; 17.22; 19.44; 17.36 score on a scale — p=<0.001

Primary: Doxycycline Concentrations in Rectal Tissues — 0.863; 2.193 µg/g

Primary: Plasma Concentration of Tenofovir (TFV) — 0; 0; 0; 0 ng/mL

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 1; 1; 0; 0 Participants

Primary: Maternal HIV Incidence — 0.38; 0.31 incidence/100 Person years

Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants

Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants

Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants

Primary: T Cell Activation — 1.8; 1.3 percentage of CD4+ T cells

Primary: Occurrence of Grade 3 or Higher Adverse Events (AEs) — 18; 24; 20; 28 Participants

Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants

Primary: Tolerability and Safety of the Treatment. — 0; 0 participants